Clinical Trial Update: A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the neurological effects of adding raltegravir to a HAART regimen in HIV patients with HIV-associated neurocognitive disorders was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Neurocognitive Disorder
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND) | Phase 4 | Status: TERMINATED | Results posted: 2014-01-03